// App-Quantinova.ai

4553 : The CD25 antibody RG6292 selectively depletes Tregs while preserving IL-2 signaling and CTL activity for tumor control

Researchers

Presenter

  • Maria Amann

Principal Investigators

  • Kolben Theresa

  • Isabelle Solomon

  • Christophe Boetsch

  • Estelle Marrer-Berger

  • Reto Flury

  • Claudio Murgia

  • Vaios Karanikas

  • Johannes Sam

  • Roger Sutmuller

  • Jan Eckmann

  • Hans Koll

  • Sara Belli

  • Frederic Arce Vargas

  • Dimitrios Zervas

  • Chen Qing

  • Mark A. Brown

  • Josephine Salimu

  • Anne Goubier

  • Sebastian Neumann

  • Karl S. Peggs

  • Sergio A. Quezada

Medical Centers

  • Roche Pharma Research & Early Development, Basel, Switzerland

  • Roche Pharma Research & Early Development, Basel, Switzerland

  • Roche Pharmaceutical Research & Early Development, Penzberg, Germany

  • University College London Hospitals/UCL Cancer Institute, London, United Kingdom

  • Black Belt Tx Ltd, Stevenage, United Kingdom

  • F. Hoffmann-La Roche Ltd., Basel, Switzerland

Locations

  • Switzerland

  • Germany

  • United Kingdom

Companies

  • N/A

Study Components

Therapeutic Area

  • Oncology (ONC)

Disease

  • Solid malignancies

Biomarkers

  • Peripheral blood mononuclear cell

  • Interleukin-2

  • Regulatory T cells

Drug/Treatment

  • Mogamulizumab

  • Basiliximab

  • Interleukin

  • Ipilimumab

  • Daclizumab

Outcome

  • N/A

Study Design

  • Superiority

Phase

  • NA

Study Id's

  • NCT04158583

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved